BioMarin and n-Lorem partner to develop ASO treatment for ReNU syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
July 27, 2026 9:05 AM EDTReNU syndrome was discovered in 2024 and there are no medicines approved for the condition
Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense expertise
Investigational antisense oligonucleotide (ASO) aims to address the underlying genetic cause of this serious neurodevelopmental condition
SAN RAFAEL, Calif. and SAN DIEGO, July 27, 2026 /PRNewswire/ --Â BioMarin Pharmaceutical Inc. (Nasdaq:... More
